

DAFTAR PUSTAKA

- Abbas, AK, Lichtman, AH, & Pillai, S. (2022). *Imunologi Seluler dan Molekuler*, pp. 44-46.
- Adam, A.A. et al. (2022) 'A Clinical Profile of Acute Coronary Syndrome Patients in Kupang', *Indonesian Journal of Cardiology*, 42(4), pp. 109–118. Available at: <https://doi.org/10.30701/ijc.1194>.
- Anumeha Singh, Museedi, A.S. and Grossman, S.A. (2023) 'Acute Coronary Syndrome', *StatPearls Publishing* [Preprint].
- Bouzidi, N. and Gamra, H. (2023a) 'Relationship between serum interleukin-6 levels and severity of coronary artery disease undergoing percutaneous coronary intervention', *BMC Cardiovascular Disorders*, 23(1), p. 586. Available at: <https://doi.org/10.1186/s12872-023-03570-8>.
- Bouzidi, N. and Gamra, H. (2023b) 'Relationship between serum interleukin-6 levels and severity of coronary artery disease undergoing percutaneous coronary intervention', *BMC Cardiovascular Disorders*, 23(1), pp. 1–9. Available at: <https://doi.org/10.1186/s12872-023-03570-8>.
- Bush, N. et al. (2021) 'Comparison of demographic profile, risk factors, and in-hospital outcome in young and old patients with acute coronary syndrome', *Journal of Family Medicine and Primary Care*, 10(2), pp. 871–876. Available at: https://doi.org/10.4103/jfmpc.jfmpc_1975_20.
- Cai, A. et al. (2015) 'Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population', *BMC Cardiovascular Disorders*, 15, pp. 1–5.
- Cao, D., Chiarito, M. and Mehran, R. (2020) 'Treating Inflammation Prior to Percutaneous Coronary Intervention', *Circulation: Cardiovascular Interventions*, 13(4), p. e009127. Available at: <https://doi.org/10.1161/CIRCINTERVENTIONS.120.009127>.
- Chan, Y.-H. and Ramji, D.P. (2020) 'A Perspective on Targeting Inflammation and Cytokine Actions in Atherosclerosis', *Future Medicinal Chemistry*, 12(7), pp. 613–626. Available at: <https://doi.org/10.4155/fmc-2019-0301>.
- Fanola, C.L. et al. (2017) 'Interleukin-6 and the risk of adverse outcomes in patients after an acute coronary syndrome: Observations from the SOLID-TIMI 52 (stabilization of plaque using darapladib-thrombolysis in myocardial infarction 52) trial', *Journal of the American Heart Association*, 6(10). Available at: <https://doi.org/10.1161/JAHA.117.005637>.
- Gültuna, S. et al. (2022) 'Lipoprotein-associated phospholipase A2 and carotid intima-media thickness in primary Sjögren syndrome', *Archives of Rheumatology*, 37(1), pp. 40–48. Available at: <https://doi.org/10.46497/ArchRheumatol.2022.8838>.
- Holst-Albrechtsen, S. et al. (2014) 'Can Lipoprotein-associated Phospholipase A₂ be Used as a Predictor of Long-term Outcome in Patients with Acute Coronary Syndrome?', *Current Cardiology Reviews*, 9(4), pp. 310–315. Available at: <https://doi.org/10.2174/1573403x09666131202143349>.
- Huang, F., Wang, K. and Shen, J. (2020) 'Lipoprotein-associated phospholipase A₂: The story continues', *Medicinal Research Reviews*, 40(1), pp. 79–134. Available at: <https://doi.org/10.1002/med.21597>.
- Kadam, V. (2019) 'Clinical profile and outcomes of patients presenting with acute coronary syndrome in a tertiary care hospital', *MGM Journal of Medical Sciences*, 6(3), p. 113. Available at: https://doi.org/10.4103/mgmj.mgmj_7_20.
- Kementrian Kesehatan (2022) 'Penyakit Jantung Penyebab Utama Kematian di

Indonesia'.

- Knuuti, J. *et al.* (2020) '2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.', *European heart journal*, 41(3), pp. 407–477. Available at: <https://doi.org/10.1093/eurheartj/ehz425>.
- Kostovska, I. *et al.* (2025) 'Role of Lipoprotein-associated phospholipase A2 (Lp-PLA2) in prediction and assessment of the severity of coronary artery disease in patients with type 2 Diabetes Mellitus Short title: Lp-PLA2 and coronary artery disease', *Journal of Medical Biochemistry*, 2(April). Available at: <https://doi.org/10.5937/jomb0-57486>.
- Law, S.H. *et al.* (2019) 'An updated review of lysophosphatidylcholine metabolism in human diseases', *International Journal of Molecular Sciences*, 20(5), pp. 1–24. Available at: <https://doi.org/10.3390/ijms20051149>.
- Li, D. *et al.* (2017) 'Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis', *Clinica Chimica Acta*, 465, pp. 22–29. Available at: <https://doi.org/10.1016/j.cca.2016.12.006>.
- Libby, P. and Bornfeldt, K.E. (2020) 'How Far We Have Come, How Far We Have Yet to Go in Atherosclerosis Research', *Circulation Research*, 126(9), pp. 1107–1111. Available at: <https://doi.org/10.1161/CIRCRESAHA.120.316994>.
- Ling, Y., Weng, H. and Tang, S. (2021) 'The relationship between IL-6 levels and the angiographic severity of coronary artery disease following percutaneous coronary intervention in acute coronary syndrome patients', *BMC Cardiovascular Disorders*, 21(1), pp. 1–8. Available at: <https://doi.org/10.1186/s12872-021-02406-7>.
- Maiolino, G. (2015) 'Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications', *World Journal of Cardiology*, 7(10), p. 609. Available at: <https://doi.org/10.4330/wjc.v7.i10.609>.
- Matter, M.A. *et al.* (2024) 'Inflammation in acute myocardial infarction: the good, the bad and the ugly', *European Heart Journal*, 45(2), pp. 89–103. Available at: <https://doi.org/10.1093/eurheartj/ehad486>.
- Menzou, F. (2022) 'Annals of Clinical Case Reports Specific Features and Clinical Profile of Acute Coronary Syndrome by Sex', *Annals of Clinical Case Report*, 7(1), p. 2153.
- Pantazi, D., Tellis, C. and Tselepis, A.D. (2022) 'Oxidized phospholipids and lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in atherosclerotic cardiovascular disease: An update.', *BioFactors (Oxford, England)*, 48(6), pp. 1257–1270. Available at: <https://doi.org/10.1002/biof.1890>.
- Pastor-Barriuso, R. *et al.* (2003) 'Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality.', *Annals of internal medicine*, 139(9), pp. 731–739. Available at: <https://doi.org/10.7326/0003-4819-139-9-200311040-00007>.
- PERKI (2022) *Panduan Prevensi Penyakit Kardiovaskular Arteriosklerosis, Perhimpunan Dokter Spesialis Kardiovaskular Indonesia 2022*.
- Qothi, I., Fuadi, M.R. and Subagjo, A. (2021) 'Profile of Major Risk Factors in Acute Coronary Syndrome (ACS) at Pusat Pelayanan Jantung Terpadu (PPJT) Dr. Soetomo Public Hospital Surabaya Between the Period of January-December 2019', *Cardiovascular and Cardiometabolic Journal (CCJ)*, 2(2), p. 59. Available at: <https://doi.org/10.20473/ccj.v2i2.2021.59-72>.
- S. Joshi, H. *et al.* (2018) 'Clinical profile of patients with acute coronary syndrome and its association with biomarker troponin I', *International Journal of Advances in Medicine*, 5(2), p. 433. Available at:

- <https://doi.org/10.18203/2349-3933.ijam20181084>.
- Sandal, G. *et al.* (2024) 'Study on Epidemiological Profile, Clinical Profile, and Angiographic Patterns in Acute Coronary Syndrome Patients in a Tertiary Health Care Center in Haryana', *World Journal of Cardiovascular Diseases*, 14(10), pp. 664–680. Available at: <https://doi.org/10.4236/wjcd.2024.1410058>.
- Saremi, A. *et al.* (2009) 'Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT)', *Atherosclerosis*, 203(2), pp. 610–614. Available at: <https://doi.org/10.1016/j.atherosclerosis.2008.07.031>.
- Shen, H. *et al.* (2025) 'Clinical value of Lp-PLA2, LDL-C, HDL-C, hs-CRP, leukocyte, FPG and HbA1c in type 2 diabetes mellitus patients with acute ischemic stroke', *Frontiers in Endocrinology*, 16(April), pp. 1–11. Available at: <https://doi.org/10.3389/fendo.2025.1546961>.
- Su, J.H. *et al.* (2021) 'Interleukin-6: A Novel Target for Cardio-Cerebrovascular Diseases', *Frontiers in Pharmacology*, 12(August), pp. 1–13. Available at: <https://doi.org/10.3389/fphar.2021.745061>.
- Supriyadi Kusumo Budoyo, D. and Sinorita, H. (2024) 'Cardiovasculoprotective Effects of Estrogen and its Use as Hormonal Replacement Therapy', *Journal of World Science*, 3(3), pp. 364–374. Available at: <https://doi.org/10.58344/jws.v3i3.568>.
- Timmis, A. *et al.* (2022) 'European Society of Cardiology: cardiovascular disease statistics 2021', *European Heart Journal*, 43(8), pp. 716–799. Available at: <https://doi.org/10.1093/eurheartj/ehab892>.
- Viana, M. *et al.* (2020) 'Patient and system delays in the treatment of acute coronary syndrome', *Revista Portuguesa de Cardiologia*, 39(3), pp. 123–131. Available at: <https://doi.org/https://doi.org/10.1016/j.repc.2019.07.007>.
- Visseren, F.L.J. *et al.* (2021) '2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.', *European heart journal*, 42(34), pp. 3227–3337. Available at: <https://doi.org/10.1093/eurheartj/ehab484>.
- Wang, X.H. *et al.* (2014) 'Correlation of serum high-sensitivity C-reactive protein and interleukin-6 in patients with acute coronary syndrome', *Genetics and Molecular Research*, 13(2), pp. 4260–4266. Available at: <https://doi.org/10.4238/2014.June.9.11>.
- World Health Organization (2022) 'Global Health Estimates: Life expectancy and leading causes of death and disability'.
- Xiang, D. *et al.* (2021) 'Protective Effects of Estrogen on Cardiovascular Disease Mediated by Oxidative Stress', *Oxidative Medicine and Cellular Longevity*, 2021. Available at: <https://doi.org/10.1155/2021/5523516>.
- Yang, C. *et al.* (2021) 'Meta-analysis of the relationship between interleukin-6 levels and the prognosis and severity of acute coronary syndrome', *Clinics*, 76(Ldl), pp. 1–7. Available at: <https://doi.org/10.6061/clinics/2021/e2690>.
- Yuan, D. *et al.* (2023) 'New Concepts on the Pathophysiology of Acute Coronary Syndrome', *Reviews in Cardiovascular Medicine*, 24(4), pp. 1–11. Available at: <https://doi.org/10.31083/j.rcm2404112>.
- Zalewski, A. and Macphee, C. (2005) 'Role of lipoprotein-associated phospholipase A2 in atherosclerosis: Biology, epidemiology, and possible therapeutic target', *Arteriosclerosis, Thrombosis, and Vascular Biology*, 25(5), pp. 923–931. Available at: <https://doi.org/10.1161/01.ATV.0000160551.21962.a7>.
- Zhang, H. *et al.* (2020) 'The relationship of lipoprotein-associated phospholipase A2 activity with the seriousness of coronary artery disease', *BMC Cardiovascular*

Disorders, 20(1), p. 295. Available at: <https://doi.org/10.1186/s12872-020-01580-4>.

Zhang, X. *et al.* (2021) 'Serum Lp-PLA2 level predicting coronary artery lesions in children with kawasaki disease', *Heart Surgery Forum*, 24(4), pp. E611–E618. Available at: <https://doi.org/10.1532/hsf.3833>.